MacroGenics Inc (NASDAQ:MGNX) – Equities research analysts at SunTrust Banks issued their FY2022 EPS estimates for MacroGenics in a research note issued on Thursday. SunTrust Banks analyst P. Lawson anticipates that the biopharmaceutical company will post earnings of ($1.39) per share for the year.
MacroGenics (NASDAQ:MGNX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.19). MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $5.50 million. During the same period last year, the business earned ($0.97) earnings per share. The firm’s revenue was down 48.5% compared to the same quarter last year.
Shares of MacroGenics (NASDAQ MGNX) traded up $0.30 on Monday, hitting $19.19. The company’s stock had a trading volume of 259,900 shares, compared to its average volume of 196,500. MacroGenics has a twelve month low of $14.36 and a twelve month high of $22.31. The firm has a market cap of $706.63, a P/E ratio of -4.27 and a beta of 2.73.
In related news, SVP Jon Marc Wigginton sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the sale, the senior vice president now directly owns 35,000 shares of the company’s stock, valued at approximately $700,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 20,000 shares of company stock valued at $400,000 over the last three months. Corporate insiders own 8.30% of the company’s stock.
Several large investors have recently modified their holdings of MGNX. Wasatch Advisors Inc. increased its position in shares of MacroGenics by 5,159.3% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,044,243 shares of the biopharmaceutical company’s stock worth $18,285,000 after purchasing an additional 1,024,388 shares during the last quarter. FMR LLC boosted its holdings in MacroGenics by 6.0% during the 2nd quarter. FMR LLC now owns 5,238,917 shares of the biopharmaceutical company’s stock valued at $91,733,000 after acquiring an additional 295,553 shares during the period. Pinnacle Associates Ltd. boosted its holdings in MacroGenics by 38.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 843,175 shares of the biopharmaceutical company’s stock valued at $15,582,000 after acquiring an additional 233,657 shares during the period. Dimensional Fund Advisors LP boosted its holdings in MacroGenics by 314.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 180,739 shares of the biopharmaceutical company’s stock valued at $3,165,000 after acquiring an additional 137,167 shares during the period. Finally, Sphera Funds Management LTD. boosted its holdings in MacroGenics by 157.0% during the 3rd quarter. Sphera Funds Management LTD. now owns 208,700 shares of the biopharmaceutical company’s stock valued at $3,857,000 after acquiring an additional 127,500 shares during the period. 85.78% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/22/macrogenics-inc-forecasted-to-earn-fy2022-earnings-of-1-39-per-share-mgnx.html.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.